Loading
HDM2017 is an experimental investigational agent whose form is not stated in the registry from Hangzhou Zhongmei Huadong Pharmaceutical in phase 2 trials for colorectal cancer, aimed at MET.
HDM2017 is an investigational agent whose form is not stated in the registry developed by Hangzhou Zhongmei Huadong Pharmaceutical. Its target is MET. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in colorectal cancer. The largest, NCT07805551, plans to enrol 220 participants with primary completion expected 2030-08. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Investigational agent whose form is not stated in the registry directed at MET, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to MET.
1.HDM2017 slips into a pocket on MET.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HDM2017" OR ABSTRACT:"HDM2017") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HDM2017, not a curated reading list.
Shares MET, Colorectal cancer and the tag pipeline.
Shares MET and the tag pipeline.
Shares MET and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.